• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    8/9/23 5:32:20 PM ET
    $ACGN
    $AHG
    $GRTX
    $INFI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Real Estate
    Real Estate
    Get the next $ACGN alert in real time by email

    Gainers

    • Vistagen Therapeutics (NASDAQ:VTGN) stock rose 22.5% to $8.62 during Wednesday's after-market session. Trading volume for this security closed at 4.6 million, accounting for 394.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $68.8 million.
    • AIM ImmunoTech (AMEX:AIM) shares rose 11.69% to $0.64. The market value of their outstanding shares is at $30.7 million.
    • Tenon Medical (NASDAQ:TNON) shares moved upwards by 10.45% to $0.26. Tenon Medical's trading volume hit 156.5K shares by close, accounting for 23.3% of its average volume over the last 100 days. The company's market cap stands at $5.6 million. The company's, Q2 earnings came out yesterday.
    • Virpax Pharmaceuticals (NASDAQ:VRPX) shares increased by 10.19% to $0.95. The market value of their outstanding shares is at $11.1 million.
    • PMV Pharma (NASDAQ:PMVP) stock increased by 10.13% to $9.55. The market value of their outstanding shares is at $437.1 million. As per the news, the Q2 earnings report came out today.
    • LogicMark (NASDAQ:LGMK) shares moved upwards by 9.31% to $2.7. The market value of their outstanding shares is at $3.4 million.

    Losers

    • Galera Therapeutics (NASDAQ:GRTX) stock declined by 83.2% to $0.38 during Wednesday's after-market session. Trading volume for this security closed at 8.6 million, accounting for 1034.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $16.1 million.
    • Organogenesis Hldgs (NASDAQ:ORGO) stock fell 41.0% to $2.0. At the close, Organogenesis Hldgs's trading volume reached 194.3K shares. This is 17.7% of its average volume over the last 100 days. The company's market cap stands at $262.5 million. As per the press release, Q2 earnings came out today.
    • Matinas BioPharma Hldgs (AMEX:MTNB) shares declined by 15.16% to $0.28. Today's trading volume for this security ended up closing at 153.6K shares, which is 32.0 percent of its average volume over the last 100 days. The company's market cap stands at $61.6 million. The company's, Q2 earnings came out today.
    • Infinity Pharmaceuticals (NASDAQ:INFI) shares decreased by 12.4% to $0.1. Infinity Pharmaceuticals's trading volume hit 2.3 million shares by close, accounting for 86.5% of its average volume over the last 100 days. The company's market cap stands at $9.0 million.
    • Akso Health Group (NASDAQ:AHG) shares declined by 11.88% to $0.32. The market value of their outstanding shares is at $7.3 million.
    • Aceragen (NASDAQ:ACGN) shares declined by 9.3% to $0.53. The company's market cap stands at $4.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACGN
    $AHG
    $GRTX
    $INFI

    CompanyDatePrice TargetRatingAnalyst
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$0.90Buy → Hold
    Jefferies
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Buy → Hold
    Maxim Group
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025Outperform → Mkt Perform
    William Blair
    Vistagen Therapeutics Inc.
    $VTGN
    12/17/2025$1.00Buy → Hold
    Stifel
    PMV Pharmaceuticals Inc.
    $PMVP
    11/8/2024$6.00Perform → Outperform
    Oppenheimer
    Organogenesis Holdings Inc.
    $ORGO
    6/28/2024$5.00Buy
    Lake Street
    PMV Pharmaceuticals Inc.
    $PMVP
    5/13/2024$6.00Buy
    Craig Hallum
    PMV Pharmaceuticals Inc.
    $PMVP
    4/12/2024$5.00Buy
    Jefferies
    More analyst ratings

    $ACGN
    $AHG
    $GRTX
    $INFI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    VistaGen downgraded by Jefferies with a new price target

    Jefferies downgraded VistaGen from Buy to Hold and set a new price target of $0.90

    12/17/25 2:23:33 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VistaGen downgraded by Maxim Group

    Maxim Group downgraded VistaGen from Buy to Hold

    12/17/25 12:23:57 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VistaGen downgraded by William Blair

    William Blair downgraded VistaGen from Outperform to Mkt Perform

    12/17/25 11:34:15 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $AHG
    $GRTX
    $INFI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LogicMark, Inc. Announces Strong Fourth Quarter and Full Year 2025 Results

    LOUISVILLE, Ky., March 25, 2026 (GLOBE NEWSWIRE) -- LogicMark, Inc. (OTC:LGMK) (the "Company"), a provider of personal safety and emergency response systems (PERS), health communications devices, and technology for the growing care and safety economy, today announced financial and operational results for the fourth quarter and year ended December 31, 2025. Fourth Quarter and Full Year 2025 Financial Highlights   Revenue: Fourth-quarter revenue increased 36% to $3.1 million. Full-year revenue increased 15% to $11.4 million. Revenue has increased year-over-year in six of the last seven quarters.Gross margin: Fourth quarter gross margin increased to 69.8%. Full-year gross margin remained st

    3/25/26 4:05:00 PM ET
    $LGMK
    Industrial Specialties
    Health Care

    Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum

    DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- Today's action highlights biotech and healthcare innovators advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global access. With the biologics market surging toward $650 billion+ by 2030 and medical tourism accelerating, today's developments showcase capital-efficient clinical progress, high-growth partnerships, and operational scaling, creating compelling narratives in precision medicine, oncology adjuvants, and AI-enabled workforce solutions. Artelo Biosciences (NASDAQ:ARTL) expands ART27.13's clinical footprint into ophthalmology through a fully funded investigator-initiated study agree

    3/18/26 10:41:39 AM ET
    $AIM
    $ARTL
    $YYGH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Professional Services

    AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors

    OCALA, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the Japan Patent Office has fully approved a Japanese patent covering the Company's proprietary use of Ampligen (rintatolimod) in combination with checkpoint inhibitors (anti-PD-1 or anti-PD-L1 antibodies) for the treatment of cancer. The patent was granted in September 2025, but had to then pass a 6-month opposition period. Japan is one of the largest health markets in the world, with Japan and the United States expected to experience the greatest increase in global pancreatic cancer burden by 2030. The Japan patent expires December 20, 2039. The allowed claims in

    3/18/26 8:36:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACGN
    $AHG
    $GRTX
    $INFI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Leibowitz Arthur S bought $13,405 worth of shares (5,000 units at $2.68), increasing direct ownership by 2% to 291,014 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    3/11/26 9:45:54 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Driscoll Michael Joseph bought $26,688 worth of shares (10,000 units at $2.67), increasing direct ownership by 5% to 225,707 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    3/11/26 5:45:41 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and President Foster Steven M bought 19,455 shares, increasing direct ownership by 568% to 22,878 units (SEC Form 4)

    4 - Tenon Medical, Inc. (0001560293) (Issuer)

    11/18/25 8:42:50 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    $ACGN
    $AHG
    $GRTX
    $INFI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Xu Jianqiang

    3 - Akso Health Group (0001702318) (Issuer)

    3/30/26 8:55:34 PM ET
    $AHG
    Real Estate

    SEC Form 3 filed by new insider Liu Wenjuan

    3 - Akso Health Group (0001702318) (Issuer)

    3/27/26 6:46:26 AM ET
    $AHG
    Real Estate

    SEC Form 3 filed by Akso Health Group

    3 - Akso Health Group (0001702318) (Issuer)

    3/18/26 5:27:12 PM ET
    $AHG
    Real Estate

    $ACGN
    $AHG
    $GRTX
    $INFI
    SEC Filings

    View All

    SEC Form 8-K filed by Galera Therapeutics Inc.

    8-K - Galera Therapeutics, Inc. (0001563577) (Filer)

    4/3/26 6:03:35 AM ET
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)

    4/2/26 4:16:35 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Matinas Biopharma Holdings Inc.

    10-K - Matinas BioPharma Holdings, Inc. (0001582554) (Filer)

    3/31/26 4:05:50 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $AHG
    $GRTX
    $INFI
    Financials

    Live finance-specific insights

    View All

    Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue

    CANTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2025. Fourth Quarter 2025 Financial Results Summary: Net product revenue of $225.1 million for the fourth quarter of 2025, an increase of $98.4 million compared to net product revenue of $126.7 million for the fourth quarter of 2024. Net product revenue for the fourth quarter of 2025 consis

    2/26/26 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026

    CANTON, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2025 financial results will be reported after the market closes on Thursday, February 26th. Management will host a conference call at 5:00 p.m. Eastern Time on February 26th to discuss the results of the quarter and the fiscal year, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live w

    2/19/26 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

    PALISADE-4 Phase 3 Trial of fasedienol for acute treatment of Social Anxiety Disorder proceeding, with topline results from the randomized portion of the trial expected in the first half of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update. "We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retraining, site rationalization, and operational en

    2/12/26 4:30:00 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $AHG
    $GRTX
    $INFI
    Leadership Updates

    Live Leadership Updates

    View All

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Vistagen Appoints Paul Edick to its Board of Directors

    Mr. Edick brings extensive industry experience across product development, commercial launch, and growth strategy Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Mr. Paul Edick to its Board of Directors ("Board"). Following the appointment of Mr. Edick, Vistagen's Board will be comprised of seven directors. Mr. Edick will serve on the Audit Committee and the Compensation Committee of the Board. "We are pleased to welcome Mr. Edick to our Board of Directors," said Maggie FitzPatrick,

    10/29/25 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

    Accomplished biopharma executive brings nearly 30 years of experience in business development, enterprise strategy, and global partnerships to her role Ms. Cote to help drive the strategic positioning of Vistagen's clinical-stage pipeline, which includes five novel intranasal pherine candidates targeting six highly prevalent and underserved disorders Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Elissa Cote as Chief Corporate Development Officer. In this role, Ms. Cote will lead t

    6/25/25 8:30:00 AM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $AHG
    $GRTX
    $INFI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by PMV Pharmaceuticals Inc.

    SC 13G - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    12/12/24 12:29:41 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by LogicMark Inc.

    SC 13D/A - LogicMark, Inc. (0001566826) (Subject)

    12/3/24 3:35:39 PM ET
    $LGMK
    Industrial Specialties
    Health Care